AI Expo: The AI Expo Europe Announces Initial Line-up of Keynote Speakers for Amsterdam Event
The AI Expo Europe is set to arrive in the hub of AI innovation, Amsterdam, The Netherlands, in under 6 weeks’ time and aims to ‘deliver AI for a smarter future.’ The leading conference and exhibition will take place in the RAI, Amsterdam on 27-28 June, with over 8,000 attendees coming together to hear keynote presentations, panel discussions and to explore the start-up innovation area, focusing on the latest innovations in the AI & IoT landscape. The AI Expo Europe Conference and Exhibition, is co-located with the IoT Tech Expo and the Blockchain Expo, so attendees can expect to learn about the convergence of three technologies that are driving IT spending in 2018.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180517005078/en/
The AI Expo Europe, the leading Artificial Intelligence conference & exhibition to arrive soon in Amsterdam. (Photo: Business Wire)
The first phase of confirmed speakers include:
- Dr. Richard Vdovjak, Principal scientist in Data Science and AI, Philips Healthcare
- Peter Jackson, Chief Data Officer, Southern Water
- Max Amordeluso, EU Lead Evangelist Alexa, Amazon
- Martine Van Der Lee, Director Social Media, KLM
- Arka Sarkar, Product Owner, Data Science, Booking.com
- Simon Poole, Head of Technology, Just Eat
- Simon Morel, Partner & Head of Product, BotSupply
- Dor Kedem, Senior Data Scientist, ING
- Filippo F.G. Della Casa, Head of Analytics, Leithà – Unipol Group
- Julio Peironcely, Head of Data Science team, Schiphol Airport
- Alex Sierkov, Director Product, Search and Machine Learning, HomeToGo
- Alexander Denev, Executive Director – Head of Quantitative Research and Advanced Analytics, IHS Markit
- Tom Ollerton, Innovation Director, We Are Social
- Daniel Gilbert, Director of Data, News UK
- Michael McDaid, Sales Director Europe, Progress DataRPM
- Britta Muzyk-Tikovsky, Managing Director, Capscovil
Over the two days, attendees can get access to a co-located exhibition with over 300 exhibitors, 18 conference tracks with a brand-new AI agenda set to feature four important strands in the AI ecosystem. These are:
The AI Expo Europe is set to be the place to network, promote and showcase your brand alongside an audience of c-suite executives and venture capitalists. Attendees who purchase an Expo Pass will have access to exclusive networking opportunities, including a VIP Delegate area at the show and a networking party, where you can network with European based innovators from around the globe.
Early bird rate ends Friday 18 th May so if you are looking for full conference and networking access, you can save up to €250 on your conference and networking pass (Gold/Ultimate) when you book then. Don’t miss the arrival of the AI Expo Europe in the thriving world-class artificial intelligence hub!
You can find out more about the World Series 2018 and register for each event here:
AI Expo Europe – 27-28 th June 2018, RAI, Amsterdam
AI Expo North America – 28-29 th November 2018, Santa Clara, Silicon Valley
AI Expo Global – 25-26 th April 2019, Olympia Grand, London
About AI Expo
The AI Expo World Series (https://www.ai-expo.net/) hosts top level content and discussion, introducing and exploring the latest innovations and strategies in the AI arena. It brings together key industries including Enterprise, Consumer, Digital Transformation, Marketing, Automotive, HR & Recruitment, Finance, Insurance, Government, Public Sector, Retail, Industrial, Healthcare, Education, Cyber Security and Developer platforms.
For speaking, sponsorship and exhibitor enquiries please contact the team at email@example.com
or call on +44 (0) 117 980 9020.
+44117 980 9020
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54 | Pressemelding
Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr
Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00 | Pressemelding
Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third